CARISMA Therapeutics Soars 36.96% on Reverse Merger News

On June 23, 2025, CARISMA Therapeutics surged 36.96% in pre-market trading, marking a significant rise in its stock price.

CARISMA Therapeutics has announced a proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen. This merger aims to create a Nasdaq-listed, late clinical-stage regenerative cell therapy company. The combined entity will focus on developing OrthoCellix's NeoCart® technology for treating knee articular cartilage defects.

The merger's financial terms include a $25 million private placement led by Ocugen and other investors, highlighting a strategic approach to risk mitigation. This move is expected to bolster CARISMA Therapeutics' position in the regenerative cell therapy market, potentially driving further growth and innovation in the field.